[1] FENG L.An observational study of cardiotoxicity in breast cancer patients using herceptin following anthracycline[D]. Jinam: Shandong University, 2018. [2] ZHOU SW.The cardiotoxicity risks of anthracycline and Trastuz-umab in HER-2 positive breast cancer patients[D]. Changchun: Jilin University, 2019. [3] SHEN SJ, XU Y, SUN Q, et al.Trastuzumab administered concurrently with anthracycline-containing adjuvant regimen for breast cancer[J]. Chinese Journal of Oncology(中国肿瘤杂志), 2014, 36(2): 132-136. [4] QU JK, ZHANG J, ZHANG J, et al.Research progress on cardio-protective drug for preventing anthracycline cardiotoxicity[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2014, 41(22): 1474-1477. [5] HU ZQ, YU WT, YAO WX, et al.Research progress on cardiotoxicity induced by antineoplastic drugs and its prevention and treatment[J]. China Pharmacy(中国药房), 2020, 31(2): 250-256. [6] ZHI G.Cardiac function monitored by echocardiography in chemotherapy patients[J]. Chinese Journal of Medical Ultrasound(Electronic Edition)[中华医学超声杂志(电子版)], 2018, 15(6): 404-408. [7] ZHAO WP, CHENG LL.Current situation and progress of echocardiography in evaluating cardiotoxicity induced by chemotherapy drugs[J]. Chinese Journal of Medical Imaging(中国医学影像学杂志), 2013, 21(10): 787-790 [8] Expert consensus on echocardiography in the treatment of cardiova-scular damage by antineoplastic therapy[J]. Chinese Journal of Ultrason-ography(中国医学影像学杂志), 2020, 29(4): 277-288. [9] LIU BB, WANG YY, MA F.Starting from oncology, analyze the development, situation and challenges of cardio-oncology[J]. Chinese Journal of Cardiovascular Medicine(中国心血管杂志), 2018, 23(5): 357-359. [10] LI XL, WANG YQ.Trastuzumab-induced cardiotoxicity and strategies for prevention and treatment[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2009, 11(4): 257-259. [11] SARO HA, CHRISTINA L, ANA B, et al.Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2017(8): 893-911. [12] LUIS ZJ, PATRIZIO L, DANIEL RM, et al.2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. European Journal of Heart Failure, 2017(1): 9-42. [13] WANG XH, LU XP.Thoughts on establishment of trans-disciplinary pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(3): 154-156. [14] YUAN L, GAO Y, LU CF.Preliminary thinking on the establishment of pharmacovigilance system in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(11): 749-752. [15] MA J, QIN S K, SHEN ZX.Guidelines for prevention and treatment of anthracycline induced cardiotoxicity (2013 Edition)[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2013, 18(10): 925-934. |